Status:
COMPLETED
Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Relapsed or Refractory Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Approximately 20% of patients diagnosed with Hodgkin lymphoma will eventually experience progression or relapse after first-line treatment, which carries a significant risk of disease-related death. A...
Detailed Description
This study is a retrospective observational multicentric study. All patients fulfilling inclusion criteria in participant centers will be included. Clinical data will be obtained from patients medical...
Eligibility Criteria
Inclusion
- Patient with relapsed or refractory HL, after at least one first line of treatment
- Aged 18 years and over
- Having received at least one course of the Brenxutimab-Vedotin J1 and Bendamustine J1 + J2 combination
Exclusion
- Minor patients
- Pregnant women
Key Trial Info
Start Date :
February 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2025
Estimated Enrollment :
222 Patients enrolled
Trial Details
Trial ID
NCT07145125
Start Date
February 1 2025
End Date
September 30 2025
Last Update
November 21 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
CH de la Côte Basque, service Hématologie Clinique
Bayonne, France
2
CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire
Bordeaux, France
3
CHU de Caen, service Hématologie Clinique
Caen, France
4
Institut Paoli Calmettes, service Hématologie Clinique
Marseille, France